LONDON — Labco, a French medical diagnostics firm, said on Wednesday that it had filed to pursue an initial public offering in Paris in the first half of this year.
The company said it would seek to list its shares on the Euronext exchange in Paris, subject to market conditions and approval by the Financial Markets Authority of France.
Labco, based in Paris, said it expected to raise at least 320 million euros, or almost $350 million, in the offering, according to documents filed with the French market regulator.
“We are delighted to reach this important milestone today,” Philippe Charrier, the Labco chief executive, said in a news release. “With this planned I.P.O., our aim is to continue the group’s growth dynamic and the rollout of our medical project based on technological innovation and operational excellence.”
Labco said that it would use proceeds from the offering to repay part of its debt and to invest in growth opportunities.
The company expects to sell shares to retail and institutional investors in France and to institutional investors elsewhere.
Labco, founded in 2003, provides medical testing services in 160 laboratories, including work for hospitals. France accounted for 53 percent of the company’s revenue in 2014.
Labco employs 6,000 people in seven countries and posted revenue of about €650 million in 2014.
The company’s largest shareholder is the British private equity firm 3i Group, which has a 17.2 percent stake.
Deutsche Bank and Morgan Stanley are serving as global coordinators on the offering.